Genenta Science
Genenta Science (NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta’s lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. For more information, visit the company's website at: www.genenta.com
Nasdaq: GNTA
IR Website: https://ir.genenta.com/
Headquarters: Milan, Italy and New York, NY
Content provided by Genenta Science on 10-1-22.
TALK TO MANAGEMENT
The Genenta Science Pharma management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Genenta Science ( NASDAQ: GNTA) is a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro-environment. Genenta’s lead product candidate, Temferon, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. For more information, visit the company's website at: www.genenta.com
Investor Presentation
Recent News
TechChill Milan, International startup & tech event
Sept 28, 2022
Chardan's 6th Annual Genetic Medicines Conference
Oct 4, 2022
Roth Capital Partners inaugural Healthcare Opportunities Conference
Oct 6, 2022
Genenta Science on track and well financed to begin phase II trial on 2023
July 19, 2022
AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative
July 25, 2022
Management Overview
Pierluigi Paracchi
Chief Executive Officer, Co-Founder
Pierluigi Paracchi is an experienced venture capital investor, Founder and CEO of Quantica SGR, co-founder of Axòn Capital and AurorA Science and previously Venture Consultant at Sofinnova Partners. He was also an investor in and Board Member of Ethical Oncology Science, which was acquired in 2013 in a total deal of $400+ million. Pierluigi is a member of the Assobiotec Executive Committee, the Italian Association for the development of biotechnology. He also serves as non-executive Director of the autoimmune disease company Altheia Science, non-executive Chairman at Lipogems International (Medical Device for Processing Adipose Tissue).
Luigi Naldini Professor,
Ph.D., M.D.
Co-Founder, Executive Scientific Board Chairman
Luigi Naldini is a renowned scientist and academic, considered as the father of the Lentivirus Gene Therapy. Luigi is Professor of Cell and Tissue Biology and Cell and Gene Therapy at the Vita-Salute San Raffaele University School of Medicine in Milan, and Director of the San Raffaele-Telethon Institute for Gene Therapy and of the Division of Regenerative Medicine, Stem Cells & Gene Therapy at the San Raffaele Scientific Institute. He has previously served as President of the European Society of Gene and Cell Therapy and a member of the Board of Directors and Advisory Council of the American Society of Gene and Cell Therapy. Luigi is also a scientific advisor on EMEA and WHO committees for the evaluation of novel gene transfer medicines and has authored more than 250 scientific publications. He won numerous awards including the Outstanding Achievement Award from the American Society of Gene and Cell Therapy (ASGCT) in 2014 and from ESGCT in 2015, the Beutler Prize from the American Society of Hematology (ASH) in 2017 and in 2019 the Jeantet-Collen Prize for Translational Medicine.
Carlo Russo, M.D.
Chief Medical Officer
& Head of Development
Carlo Russo is a biotech executive with vast experience in research & development in large pharma companies, including GSK, Merck and Biotech. He has served as Head of Development of GSK’s R&D Biopharm and Rare Disease Units, the Head of Cardiovascular Metabolic Center and the founder & Head of the Alternative Development Programs. He was Executive VP and CMO of Adverum, CMO & Head R&D of Annapurna and President and CEO of VaxInnate Corporation, among other senior roles. Carlo holds a number of senior positions at research institutions, including Cornell University Medical College, Columbia University and Scripps Research Institute. He holds his MD and Board Certification in Hematology from the University of Genoa Medical School and is the author of more than 70 scientific publications.
Richard B. Slansky
Chief Financial Officer
Richard Slansky is a senior financial executive with more than 30 years of experience as Chief Financial Officer in various biopharmaceutical diagnostic and life science companies, including Oncosec, Biological Dynamics and Genmark Diagnostics. His experience spans public and private companies, pre-revenue to revenue growth, and commercial healthcare and high technology environments. He has been responsible for strategic vision and oversight of financial and operational teams, organizational leadership and creating maximum stakeholder value. He also serves on the Board of Directors of several private companies, including Nuclear RNA Networks, an early-stage RNA gene transcription therapeutics company.
Stefania Mazzoleni Ph.D.
Scientific Project Manager & Communication Officer
Stefania Mazzoleni currently serves as Scientific Project Manager & Communication Officer at Genenta where she manages and oversees the scientific development of parallel immuno-gene therapy studies in oncology indications and provides scientific support for Investor interactions, by combining deep pre-clinical and scientific area-specific knowledge to clinical research experience. Stefania has more than 15 years’ experience in life science R&D, oncology and project management, including more than 4 years in drug development and cell & gene therapy from various academic institutions and pharmas. Stefania received a MsC in Medical Biotechnology, holds her Ph.D. in Molecular and Cellular Biology from San Raffaele Vita-Salute University, has a Second level vocational Master’s in Pharmacy and Pharmaceutical Oncology and is a member of the European Academy of Tumor Immunology (EATI).
Tim Obara
Head of Business Development
Tim Obara brings over 30 years of pharmaceutical industry sector and academia experience to Genenta, including therapeutic area experience in cardiovascular, oncology, vaccines and cell and gene therapy programs. In leading the Business Development efforts he will collaborate with the Genenta leadership team, to identify, evaluate and work with external partners on our pipeline assets. Tim joins Genenta from the University of Pennsylvania Gene Therapy Program, where he was Executive Director of Research Operations. He has previously worked in senior business development, corporate strategy, commercial and CMC roles at Merck, GSK, AstraZeneca, Tessa Therapeutics and Amicus Therapeutics.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Genenta Science (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
